How Wegovy Works Differently
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the GLP-1 hormone to slow gastric emptying, reduce appetite, and regulate blood sugar. Unlike older drugs like phentermine (an appetite suppressant) or orlistat (a fat absorption blocker), Wegovy targets multiple pathways in the brain and gut for sustained hunger control, leading to 15-20% average body weight loss in trials versus 5-10% for many alternatives.[1][2]
Wegovy vs. Ozempic and Other Semaglutides
Wegovy is essentially higher-dose Ozempic (both from Novo Nordisk), approved specifically for weight loss at up to 2.4 mg weekly injections, while Ozempic caps at 2 mg for diabetes. Mounjaro (tirzepatide from Eli Lilly) adds GIP receptor action for potentially greater loss (up to 22%), but Wegovy has longer real-world use data.[1][3]
| Drug | Active Ingredient | Mechanism | Avg. Weight Loss | Approval |
|------|-------------------|-----------|------------------|----------|
| Wegovy | Semaglutide | GLP-1 only | 15-20% | Obesity (2021) |
| Ozempic | Semaglutide | GLP-1 only | 10-15% (off-label) | Diabetes |
| Mounjaro/Zepbound | Tirzepatide | GLP-1 + GIP | 20-22% | Diabetes/obesity |
| Saxenda | Liraglutide | GLP-1 | 5-10% | Obesity |
| Phentermine | Various | Appetite suppressant | 5-8% (short-term) | Short-term obesity |
Why Clinical Results Stand Out
In the STEP trials, Wegovy users lost more weight and kept it off longer than with liraglutide (Saxenda) or placebo, with benefits like improved heart health in select patients. Alternatives like Contrave (naltrexone-bupropion) or Qsymia show less loss and higher dropout rates due to side effects.[2][4]
Common Side Effects Compared
All GLP-1 drugs like Wegovy cause nausea, vomiting, and diarrhea (affecting 20-40% initially), but these fade faster than with older stimulants. Mounjaro may hit GI issues harder early on; phentermine risks insomnia and blood pressure spikes. Rare pancreatitis or thyroid concerns apply across GLP-1s.[1][3]
Cost and Access Differences
Wegovy lists at $1,300-$1,700 monthly without insurance, similar to Zepbound but pricier than generics like phentermine ($50/month). Novo Nordisk offers coupons dropping it to $0-$500 for eligible patients; shortages have eased but persist.[5]
Patent Protection and Biosimilar Timeline
Wegovy's key patents on semaglutide formulations expire in the late 2030s, with Novo defending against challenges from Indian generics. No approved biosimilars yet, unlike older drugs with generics available now. Check DrugPatentWatch.com for expiry details and litigation updates.[6]
[1] FDA.gov - Wegovy Label
[2] NEJM - STEP 1 Trial (2021)
[3] FDA.gov - Zepbound Label
[4] JAMA - Comparative Efficacy Review (2023)
[5] GoodRx Pricing Data (2024)
[6] DrugPatentWatch.com - Semaglutide Patents